EGFR MUTATION DETECTION - REAL TIME PCR

EGFR Mutation Detection - Real Time PCR is an advanced molecular diagnostic test used to identify mutations in the Epidermal Growth Factor Receptor (EGFR) gene. These mutations are commonly associated with certain types of cancer, particularly non-small cell lung cancer (NSCLC), and play a critical role in selecting targeted therapies that can improve treatment outcomes.

The test utilizes highly sensitive Real-Time Polymerase Chain Reaction (RT-PCR) technology to detect specific EGFR gene mutations with high accuracy. Identification of EGFR mutations helps oncologists determine whether a patient may benefit from EGFR-targeted therapies, enabling a personalized approach to cancer treatment.

Benefits of the Test

• Accurately detects clinically significant EGFR mutations.
• Supports personalized cancer treatment planning.
• Helps identify patients eligible for targeted therapy.
• Provides rapid and reliable molecular results.
• Assists oncologists in treatment decision-making.
• Reduces unnecessary exposure to ineffective therapies.
• Supports precision oncology approaches.
• Improves cancer management strategies.

Why Doctors Recommend This Test

Doctors recommend EGFR Mutation Detection testing for patients diagnosed with non-small cell lung cancer and selected other cancers where EGFR mutation analysis may influence treatment decisions. The test helps determine eligibility for EGFR-targeted medications and supports individualized treatment planning.

Accurate mutation identification allows clinicians to choose therapies that specifically target the underlying genetic alterations driving cancer growth.

Preparation Before Test

• No fasting is generally required.
• A tissue biopsy specimen or appropriate tumor sample is usually required.
• In some cases, blood-based samples may be accepted depending on clinical requirements.
• Provide relevant pathology and medical records.
• Inform your doctor about ongoing cancer treatments.
• Follow all specimen collection and submission guidelines.

Normal Reporting Time

Most EGFR Mutation Detection - Real Time PCR reports at Focus Diagnostics are available within 2–3 hours for specimen processing and molecular workflow initiation. Final mutation analysis, validation, and reporting generally require several working days depending on specimen quality and laboratory protocols.

Who Should Take This Test?

This test may be recommended for:

• Patients diagnosed with non-small cell lung cancer (NSCLC).
• Individuals being evaluated for targeted cancer therapy.
• Patients with advanced or metastatic lung cancer.
• Individuals requiring molecular tumor profiling.
• Cancer patients undergoing precision medicine evaluation.
• Patients with recurrent or progressive disease.
• Individuals requiring genetic mutation assessment.
• Patients referred by oncologists for treatment planning.

Detailed Information

The Epidermal Growth Factor Receptor (EGFR) gene provides instructions for producing a protein involved in cell growth, survival, and division. Mutations within the EGFR gene can cause abnormal signaling pathways that promote uncontrolled cell proliferation and cancer development. These mutations are particularly common in certain cases of non-small cell lung cancer.

EGFR mutation testing has become an essential component of modern oncology because specific EGFR mutations may predict response to targeted therapies known as EGFR tyrosine kinase inhibitors (TKIs). These treatments are designed to specifically block abnormal EGFR signaling pathways and may offer improved outcomes compared with conventional therapies in appropriately selected patients.

EGFR Mutation Detection - Real Time PCR uses highly sensitive molecular technology to identify common clinically actionable mutations within the EGFR gene. Real-time PCR enables rapid amplification and detection of genetic alterations with excellent analytical performance and diagnostic accuracy.

The test is typically performed on tumor tissue obtained through biopsy or surgical procedures. In selected clinical situations, liquid biopsy samples may also be used for mutation analysis. Results help oncologists determine whether targeted treatment options are likely to be effective and assist in developing individualized treatment strategies.

Common EGFR mutations include exon 19 deletions, exon 21 L858R mutations, and other clinically relevant alterations that may influence therapeutic decisions. Identifying these mutations can significantly impact treatment selection and prognosis.

Results should always be interpreted together with pathology findings, imaging studies, clinical history, tumor stage, and other molecular diagnostic results. Additional biomarker testing may also be recommended depending on the type of cancer being evaluated.

At Focus Diagnostics, EGFR Mutation Detection - Real Time PCR testing is performed using advanced molecular oncology platforms, validated PCR methodologies, and stringent quality assurance standards to provide accurate, reliable, and clinically meaningful genetic results for cancer management.